Mouse IL-7 ELISA kit (4X96T)
- Known as:
- Mouse Interleukin-7 Enzyme-linked immunosorbent assay test reagent (4X96T)
- Catalog number:
- LF-EK50656
- Product Quantity:
- 4
- Category:
- Elisa Kits
- Supplier:
- Abfron
- Gene target:
- Mouse IL-7 ELISA kit (4X96T)
Related genes to: Mouse IL-7 ELISA kit (4X96T)
- Gene:
- IL7 NIH gene
- Name:
- interleukin 7
- Previous symbol:
- -
- Synonyms:
- IL-7
- Chromosome:
- 8q21.13
- Locus Type:
- gene with protein product
- Date approved:
- 1989-10-12
- Date modifiied:
- 2016-10-11
- Gene:
- IL7R NIH gene
- Name:
- interleukin 7 receptor
- Previous symbol:
- -
- Synonyms:
- CD127, IL7RA
- Chromosome:
- 5p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1991-08-07
- Date modifiied:
- 2019-04-23
Related products to: Mouse IL-7 ELISA kit (4X96T)
Related articles to: Mouse IL-7 ELISA kit (4X96T)
- Individuals with cystic fibrosis (CF) are vulnerable to environmental exposures due to impaired pulmonary defense mechanisms, yet the contribution of the indoor environment to inflammatory signaling in CF remains poorly understood. While prior studies have focused on ambient air pollution and clinical outcomes, less is known about how short-term indoor particulate matter exposure relates to systemic immune biomarkers. In this pilot study, we evaluated associations between household fine particulate matter (PM) concentrations and circulating cytokines in adults with CF. Participants underwent four to eleven days of in-home PM monitoring using real-time air quality sensors. Circulating inflammatory cytokines were measured from blood samples collected using a multiplex immunoassay. PM exposure was characterized using two metrics: mean PM concentration across the monitoring period and the percentage of monitoring time with indoor PM>35 μg/m. Associations between PM exposure and cytokine concentrations were assessed using Spearman rank correlations. While mean PM concentration was not associated with cytokine levels, the percentage of monitoring time with indoor PM>35 μg/m was associated with variation in circulating cytokines. PDGF-AA/BB suggested a moderate, statistically significant positive correlation with the percentage of monitoring time with PM>35 μg/m, while IL-7 and IL-8 showed positive but non-significant trends. TNF-α exhibited a non-significant negative association. These findings suggest that time spent at elevated indoor PM concentrations may be relevant to systemic inflammatory signaling in adults with CF and support further investigation into modifiable indoor environmental exposures. - Source: PubMed
Publication date: 2026/09/26
Zhang MichaelSmolen Kali AChittineni Midhuna SreeHampton Thomas HTaub LilyMellinger DianeAridgides Daniel SAshare AlixPaulin Laura M - Ulcerative colitis (UC) remains difficult to control in a substantial proportion of patients despite an expanding range of advanced therapies. Interleukin-7 (IL-7) is a homeostatic cytokine that supports lymphocyte survival, persistence and intestinal trafficking through signalling via IL-7 receptor-α (IL-7Rα; CD127), providing a rationale for selective pathway inhibition in chronic intestinal inflammation. This narrative review examines the biology of IL-7/IL-7R signalling in inflammatory bowel disease (IBD) and summarises the preclinical, translational and clinical development of lusvertikimab, a humanised monoclonal antibody targeting IL-7Rα. MEDLINE was searched from inception to 31 July 2026, supplemented by reference-list screening, trial registries, conference proceedings and regulatory sources. Experimental studies show that IL-7 supports the persistence of colitogenic effector-memory T cells and contributes to innate immune activation. Human translational data demonstrate enrichment of IL-7R pathway activity in treatment-refractory IBD, association with anti-TNF non-response, and IL-7-mediated upregulation of the gut-homing integrin α4β7. Preclinical IL-7R blockade attenuated experimental colitis, reduced intestinal T-cell trafficking and altered inflammatory responses in UC tissue. In a first-in-human study, lusvertikimab produced sustained receptor occupancy and suppression of IL-7-associated gene expression without broad lymphocyte depletion. In the phase II CoTikiS trial, lusvertikimab improved Modified Mayo Score versus placebo, with significant pooled endoscopic improvement but no significant pooled differences in clinical or endoscopic remission. Early safety findings were reassuring. Selective IL-7Rα blockade therefore represents a biologically distinct therapeutic strategy in UC, although larger controlled studies, biomarker validation and clarification of dose selection and long-term safety are required to define its clinical role and whether combination strategies warrant future evaluation in selected patients. - Source: PubMed
Publication date: 2026/09/20
Manti MagdaliniRaspa ValentinaPatel KamalHonap Sailish - We sincerely thank Dr [...]. - Source: PubMed
Publication date: 2026/09/15
Panikar Sandeep SurendraBansal DhruvCrandall JohnRaman HariPicus JoelIppolito Joseph EThorek Daniel L JWahl Richard LPachynski Russell K - We read with great interest the article by Panikar et al [...]. - Source: PubMed
Publication date: 2026/09/14
Çınar Alev - Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, and current therapeutics provide limited benefits to patients. Desmoplasia and the highly immunosuppressive tumor microenvironment (TME) play a huge role in PDAC being elusive to current therapeutics. Here, we strategically selected four transgenes to express from adenovirus vectors to target desmoplasia and the highly immunosuppressive TME in PDAC: interferon gamma (IFNγ), extracellular domain of transforming growth factor beta receptor 2 (sTGFβRII), interleukin 7 (IL7), and the extracellular domain of T-cell Immunoglobulin and Mucin domain-containing protein 3 (sTIM3). We used an immunocompetent syngeneic mouse model harboring tumors derived from KPC cells, a common mouse pancreatic cancer cell line, to test the anti-tumor effects of our transgene-expressing Ad vectors. We showed that all four transgenes elicited significant anti-tumor effects and shifted the tumors to a more immunogenic profile by increasing intratumoral expression of immune activation proteins and infiltration of anti-tumor immune cells. Furthermore, inhibition of desmoplasia was observed in three of four proteins. Of the four transgenes analyzed, IFNγ and sTGFβRII induced the greatest anti-tumor results and were combined in a single Ad vector. This dual-expressing Ad vector elicited the greatest anti-tumor effect, increase in immunogenicity, decrease in fibrosis, and showed abscopal effects. These results provide insight into how the analyzed transgenes can favorably alter the TME in pancreatic cancer patients and show encouraging potential when combined with other therapeutic regimens. - Source: PubMed
Publication date: 2026/09/24
Roach Brett LSato-Dahlman MizuhoJacobsen KariGates TravisShanley RyanStromnes Ingunn MYamamoto Masato